In:
Urologia Internationalis, S. Karger AG, Vol. 72, No. 3 ( 2004), p. 203-207
Abstract:
〈 i 〉 Background: 〈 /i 〉 E-cadherin is an epithelial cell adhesion molecule, and decreased E-cadherin expression in human prostate cancer is associated with tumor grade and advanced clinical stage. A –160 C→A polymorphism in the promoter region of 〈 i 〉 E-cadherin 〈 /i 〉 has been shown to decrease gene transcription. This allelic variation may be a potential genetic marker that can help identify those individuals at higher risk for invasive/metastatic disease. 〈 i 〉 Materials and Methods: 〈 /i 〉 We studied the effect of 〈 i 〉 E-cadherin 〈 /i 〉 gene polymorphism on prostate cancer susceptibility in a case control study of 219 prostate cancer patients and 219 male controls, to determine whether this polymorphism is a biomarker for the risk and how aggressive the disease is. 〈 i 〉 Results: 〈 /i 〉 The genotype frequencies in the prostate cancer group were C/C: 0.607, C/A: 0.352, A/A: 0.041, and in the control group C/C: 0.671, C/A: 0.301, A/A: 0.027. A significant difference between the two groups was not found (p = 0.34), and the adjusted OR for A/A genotype was not statistically significant (OR = 1.66, 95% CI 0.58–4.78). Subdividing prostate cancer according to tumor differentiation and stage, we found no association between 〈 i 〉 E-cadherin 〈 /i 〉 polymorphism and poor differentiation and invasiveness of prostate cancer. 〈 i 〉 Conclusions: 〈 /i 〉 These data do not support an association between the 〈 i 〉 E-cadherin 〈 /i 〉 genotype and the occurrence or progression of prostate cancer in Japanese populations.
Type of Medium:
Online Resource
ISSN:
0042-1138
,
1423-0399
Language:
English
Publisher:
S. Karger AG
Publication Date:
2004
detail.hit.zdb_id:
1464417-4
Permalink